DE60237275D1 - Vegf und hgf exprimierenden nukleinsäurekonstrukte, damit transformierte zellen und dieser verwendung zur induzierung der leberregeneration und linderung von pfortaderhochdruck - Google Patents

Vegf und hgf exprimierenden nukleinsäurekonstrukte, damit transformierte zellen und dieser verwendung zur induzierung der leberregeneration und linderung von pfortaderhochdruck

Info

Publication number
DE60237275D1
DE60237275D1 DE60237275T DE60237275T DE60237275D1 DE 60237275 D1 DE60237275 D1 DE 60237275D1 DE 60237275 T DE60237275 T DE 60237275T DE 60237275 T DE60237275 T DE 60237275T DE 60237275 D1 DE60237275 D1 DE 60237275D1
Authority
DE
Germany
Prior art keywords
porto
hgf
vegf
relating
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60237275T
Other languages
English (en)
Inventor
Moshe Y Flugelman
Zoya Gluzman
Meir Preis
Belly Koren
Tzafra Cohen
Adili Tsaba
Michael Ott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Multi Gene Vascular Systems Ltd MGVS
Original Assignee
Multi Gene Vascular Systems Ltd MGVS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Multi Gene Vascular Systems Ltd MGVS filed Critical Multi Gene Vascular Systems Ltd MGVS
Application granted granted Critical
Publication of DE60237275D1 publication Critical patent/DE60237275D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M2025/1043—Balloon catheters with special features or adapted for special applications
    • A61M2025/1052—Balloon catheters with special features or adapted for special applications for temporarily occluding a vessel for isolating a sector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
DE60237275T 2001-03-02 2002-02-28 Vegf und hgf exprimierenden nukleinsäurekonstrukte, damit transformierte zellen und dieser verwendung zur induzierung der leberregeneration und linderung von pfortaderhochdruck Expired - Lifetime DE60237275D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/796,543 US20020164310A1 (en) 2001-03-02 2001-03-02 Nucleic acid constructs, cells transformed therewith and methods utilizing same for inducing liver regeneration and alleviation of portal hypertension
PCT/IL2002/000153 WO2002070019A1 (en) 2001-03-02 2002-02-28 Nucleic acid constructs, cells transformed therewith and methods utilizing same for inducing liver regeneration and alleviation of portal hypertension

Publications (1)

Publication Number Publication Date
DE60237275D1 true DE60237275D1 (de) 2010-09-23

Family

ID=25168443

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60237275T Expired - Lifetime DE60237275D1 (de) 2001-03-02 2002-02-28 Vegf und hgf exprimierenden nukleinsäurekonstrukte, damit transformierte zellen und dieser verwendung zur induzierung der leberregeneration und linderung von pfortaderhochdruck

Country Status (7)

Country Link
US (2) US20020164310A1 (de)
EP (1) EP1370299B1 (de)
AT (1) ATE476999T1 (de)
CA (1) CA2439584A1 (de)
DE (1) DE60237275D1 (de)
IL (1) IL157639A0 (de)
WO (1) WO2002070019A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2486270C (en) * 2002-06-05 2015-07-28 Genentech, Inc. Vegfr modulating agents and methods for liver growth and liver protection
US8399441B2 (en) 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
EP1948247A4 (de) * 2005-11-15 2010-07-07 Univ Leland Stanford Junior Zusammensetzungen zur koordinierten vegf- und pdgf-expression sowie verwendungsverfahren dafür
US20100093018A1 (en) * 2007-04-26 2010-04-15 Achillion Pharmaceuticals, Inc. Cells expressing chimeric proteins and assays using such cells
EP2155860B1 (de) 2007-05-03 2014-08-27 The Brigham and Women's Hospital, Inc. Multipotente stammzellen und ihre verwendung
US8574567B2 (en) 2007-05-03 2013-11-05 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
US8152755B1 (en) * 2010-03-24 2012-04-10 Cell Precision LLC System and method for delivering a therapeutic agent with finesse
US9034859B2 (en) * 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
TWI816417B (zh) 2013-12-24 2023-09-21 維吉尼亞聯邦大學 氧化膽固醇硫酸鹽（ｏｃｓ）之用途
KR20230152787A (ko) 2016-08-02 2023-11-03 버지니아 커먼웰스 유니버시티 5-콜레스텐-3, 25-디올, 3-술페이트 (25hc3s) 또는 이의 약학적으로 허용 가능한 염, 및 적어도 하나의 시클릭 올리고당을 포함하는 조성물
US20220145258A1 (en) 2020-11-10 2022-05-12 Vessl Therapeutics Ltd Methods of preconditioning vascular cells for transduction, methods of transduction and methods of preserving transduced cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006456A1 (en) 1992-09-16 1994-03-31 Genentech, Inc. Protection against liver damage by hgf
JP4642303B2 (ja) 1999-09-21 2011-03-02 アンジェスＭｇ株式会社 脳血管障害のための遺伝子治療
WO2002002148A2 (en) * 2000-06-30 2002-01-10 Collateral Therapeutics, Inc. Dual recombinant gene therapy compositions and methods of use

Also Published As

Publication number Publication date
EP1370299A4 (de) 2004-07-28
US20040116343A1 (en) 2004-06-17
US20020164310A1 (en) 2002-11-07
EP1370299A1 (de) 2003-12-17
US7524493B2 (en) 2009-04-28
CA2439584A1 (en) 2002-09-12
WO2002070019A1 (en) 2002-09-12
ATE476999T1 (de) 2010-08-15
IL157639A0 (en) 2004-03-28
WO2002070019A8 (en) 2003-11-27
EP1370299B1 (de) 2010-08-11

Similar Documents

Publication Publication Date Title
DE60237275D1 (de) Vegf und hgf exprimierenden nukleinsäurekonstrukte, damit transformierte zellen und dieser verwendung zur induzierung der leberregeneration und linderung von pfortaderhochdruck
ATE315420T1 (de) Elektrodenleitung zur stimulation von wirbelsaülen
DE60238493D1 (de) Is von seltenen zellen verwendete markierte zellen
NO20025402D0 (no) Modifiserte ES-celler og ES-spesifikt gen
DE50210133D1 (de) Retina-implantat mit elektrodenanordnung zur elektrischen stimulation von biologischem material
ATE342071T1 (de) Implantat mit poröser proteinmatrix und verfahren zu seiner herstellung
CY1105070T1 (el) Μεθοδος και συνθεσεις που χρησιμοποιουν κιναζολινονες
DE60326874D1 (de) Neue verwendung von erythropoietin in herzerkrankungen
ATE278796T1 (de) Pufferlössung für die elektroporation und verfahren umfassend die verwendung derselben
ATE446719T1 (de) Vorrichtung zur ausbrennung von gewebe
EA200401591A1 (ru) Керамические аноды и способ их изготовления
DE60135019D1 (de) Elektroverarbeitetes kollagen
ATE535542T1 (de) Gen-regulierende peptide
CY1112330T1 (el) Πρωτεϊνες συνδεσης gag
DE60124974D1 (de) Elektrodenkatalysator und elektrochemische Vorrichtungen unter Verwendung derselben
DE60118433D1 (de) Implantierbare medizinische vorrichtung zur überwachung von kongestiver herzinsuffizienz
DE50214416D1 (de) Vermehrung von viren in zellkultur
ATE313634T1 (de) Verfahren zur herstellung von rekombinanten proteinen mittels inhibitoren von apoptose
ATE543617T1 (de) Herstellung und verwendung von mikroperforierten substraten
DK1315537T3 (da) Fremgangsmåde og system til myokardieinfarktreparation
DE502004009820D1 (de) Behältnis und Vorrichtung zur Erzeugung von elektrischen Feldern in einzelnen Reaktionsräumen
DE60222590D1 (de) Methoden zur feststellung von akute myeloischen leukämie
DE60043609D1 (de) Neuartige pharmakologische aktivitäten von curcuma longa extrakten
DE60230774D1 (de) Isolierung von nervenstammzellen unter verwendung von gangliosiden und anderen oberflächenmarkern
ATE309356T1 (de) Konstruierte fluoreszenzproteine mit langen wellenlängen